Vectra 3D


dinotefuran, permethrin, and pyriproxyfen

This medicine is authorised for use in the European Union.


This is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 06/09/2018

Authorisation details

Product details
Vectra 3D
Agency product number
Active substance
dinotefuran, permethrin, and pyriproxyfen
International non-proprietary name (INN) or common name
dinotefuran, permethrin, and pyriproxyfen
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Ceva Sante Animale
Date of issue of marketing authorisation valid throughout the European Union
Contact address
10 Av. de la Ballastière
33501 Libourne

Product information

27/08/2018 Vectra 3D - EMEA/V/C/002555 - R/0009


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Ectoparasiticides for topical use

Therapeutic indication

  • Treatment and prevention of flea infestation (Ctenocephalides felis and Ctenocephalides canis);
  • Treatment and prevention of tick infestation (Rhipicephalus sanguineus, Dermacentor reticulatus, Ixodes ricinus);
  • Sand fly bite prevention (Phlebotomus perniciosus) and mosquito bite prevention (Culex pipiens, Aedes aegypti);
  • Treatment and prevention of stable fly infestation (Stomoxys calcitrans).

Assessment history

How useful was this page?

Add your rating
1 rating